BDSX

BiodesixC

Nasdaq / Health Care Equipment & Services

At close

2026-07-20

Current thesis

If the Q1 2026 release confirms another clean revenue-growth quarter, maintains the FY2026 revenue framework introduced with Q4 2025 results, and shows cash usage continuing to moderate, BDSX can keep a speculative recovery case alive from a depressed market cap base.

Posture

Mixed

Lead driver

Momentum

What changed

Momentum remains the lead driver in the composite, 7D delta +0.2.

What can break

As of May 4, 2026, the actual Q1 2026 earnings release was not yet confirmed on the company quarterly-results page, so the surprise and guidance read-through remain open.

Momentum

Value

Sentiment

Setup hits (3d)

0 · Net Neutral

AI TargetsBase $11.50 · Bull $14.00 · Bear $8.00

Data freshness

Prices

As of 2026-07-20

Fundamentals

As of 2026-07-20 • Vendor: Data Vendor v1

Scores

As of 2026-07-20 • Model: HYBRID_IC_RP

AI Memo

As of 2026-05-04 • Model: RankAlpha Sentiment Codex

Investment thesis

As of 2026-07-20

Supporting evidence

What

Grade C · Mixed

Confidence Medium · Net Neutral

Target $30.83

Why

Momentum97 · Δ7d +0.2

Value37 · Δ7d -0.0

Sentiment28 · Δ7d +2.1

So what

Balanced signals (Net Neutral). Wait for confirmation before sizing up.

Lead driver: Momentum · See technicals

Momentum

26% active weight

Current posture

7d trendFlat

Δ7d

+0.2

Δ21d

Value

39% active weight

Current posture

7d trendFlat

Δ7d

-0.0

Δ21d

+0.1

Sentiment

34% active weight

Current posture

7d trendImproving

Δ7d

+2.1

Δ21d

Why this grade

Composite grade C. Momentum 96.6 / Value 36.5 / Sentiment 27.9

Fundamentals (TTM)

As of 2026-07-20

Market Cap

$205.15M

Beta

0.65

Shares Out

10.36M

P/E (TTM) · Derived

-4.2

P/S (TTM)

0.62

P/FCF (TTM) · Derived

-6.45

Rev YoY

+42.3%

EPS YoY

-46.7%

Gross Margin

+82.1%

Op Margin

-40.6%

Net Debt

$53.77M

Current Ratio

2.82

As of 2026-07-20 • Updated nightlySource: Internal modelMethodology